Daiichi Sankyo to seal Ranbaxy deal early
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's acquisition of Ranbaxy Laboratoriesappears set for closure ahead of schedule, after a committee of the Ranbaxy board approved the allocation of equity shares and warrants on a preferential basis to Daiichi Sankyo.